



OPEN

Unlocking the access to oxidized coenzyme A via a single-step green membrane-based purification

Louis M. M. Mouterde[✉], Gaëlle Willig, Maxime M. J. Langlait, Fanny Brunois, Morad Chadni & Florent Allais

A new membrane-based strategy to purify oxidized coenzyme A ((CoAS)₂) from adenosine triphosphate (ATP), adenosine diphosphate (ADP) and adenosine monophosphate (AMP) has been developed. Commercially available membranes were screened and studied (permeate flux and overall compounds retention) which allowed the identification of one efficient membrane (GK from Suez Water Technologies & Solutions). Different total compounds concentrations solutions were used in the system in order to find the following working conditions: 4 bars with a total compounds solution of 5.19 g L⁻¹. Applying these conditions to a dia-filtration set-up allowed us to reach 68% pure (CoAS)₂ in 4.8 diafiltration volumes (DV) and a 95% (CoAS)₂ purity can be predicted in 8.5 DV. A comparative study of green metrics—i.e. process mass index (PMI)—of the classic chromatography vs the membrane-based one demonstrated the great advantages of the latter in terms of sustainability. This strategy unlocks the access to the essential and central cofactor that is coenzyme A.

In the last decades, industrial biotechnologies have experienced a strong and ever-expanding development to offer sustainable alternatives to chemical processes that are not always respectful of the environment and most often dependent on fossil resources. Fermentation has been shown to be effective for the production of valuable products such as biofuels, therapeutic molecules or food additives^{1–10}. However, it can suffer from some limitations such as substrate/product working concentrations (e.g., toxicity towards the microorganism, transfer of the substrate/product through the microorganism membrane), fermentation conditions or downstream processing (e.g., presence of biomass, primary and secondary metabolites). In vitro biocatalysis is a good strategy to implement when these limitations become insuperable.

The great advances achieved in protein engineering and enzyme immobilization allowed the development of robust systems in pharmaceutical, food processing or detergent industries^{11–23}. However, enzymes that lead to such systems are very rarely coenzyme-dependent, mainly due to the high commercial cost of these molecules. This is the case for coenzyme A (CoA, *ca.* > \$2000/gram) which is involved in many metabolic pathways such as fatty acid synthesis and degradation, amino-acid degradation or oxidation of pyruvate in the Krebs cycle. All genome sequenced to date encode enzymes that necessarily require CoA which represents 4% of known enzymes²⁴. These are all potential enzymatic tools that cannot be exploited in vitro systems. It is especially important as alternative biocatalytic C–C bonds forming methods (identified in many metabolic pathways involving CoA) are needed to substitute classical chemical methods, such as aldol reactions or Claisen condensations, that involves toxic and non-sustainable chemicals/solvents. Although gram-scale in vivo and in vitro production methods have been developed to increase the availability of CoA^{25–32}, they did not sufficiently lower the process cost mainly due to the expensive purification methods required³³. Indeed, the latter consist in using different ion exchange chromatography steps and charcoal adsorption/desorption in order to isolate CoA from cellular materials and/or metabolites/coproducts such as adenosine triphosphate (ATP), adenosine diphosphate (ADP) and adenosine monophosphate (AMP)^{26,32,34–36} (Fig. 1). The ion exchange chromatography used to separate these adenosine-based compounds is particularly challenging due to the very similar ionic profile of the molecules. Such method has also been used to purify oxidized CoA ((CoAS)₂) which present the great advantage of being highly stable compared to CoA and that can give access to the latter through a trivial disulfide bridge reduction³².

In this work, an alternative separation method that do not require additional salts other than the ones needed for the biocatalytic production of (CoAS)₂, solvent nor chemical compounds, and that takes advantage of both the differences in molecular weights between the reaction mixture products and the stability of (CoAS)₂, has

URD Agro-Biotechnologies Industrielles (ABI), CEBB, AgroParisTech, 51110 Pomacle, France. ✉email: louis.mouterde@agroparistech.fr




Figure 1. Structures of the coenzyme A, (CoAS)₂, ATP, ADP and AMP.




Figure 2. Effect of pressure (TMP) on permeate flux (J_v) for membranes screened with model solution. **(A)** (●) NP010, (●) GE, (●) 7450, (●) 7470 PHT. **(B)** (●) GK, (●) GR95PP.

been investigated^{32,36}. According to the aforementioned considerations, a cross-flow dia-ultrafiltration was implemented to efficiently and readily separate (CoAS)₂ from ATP, ADP and AMP. It must be noted that this strategy would allow an affordable access to (CoAS)₂ which can only be found nowadays at a very high-cost (*ca.* > \$30,000/gram).

Results

Membrane selection. The first step of the study consisted in a screening of different membranes using a model solution composed of (CoAS)₂, ATP, ADP and AMP to evaluate their ability to retain (CoAS)₂ and to discard ATP, ADP and AMP in a cross-flow diafiltration setup, the molecular weight of the target molecule being 1533 g mol⁻¹ and the one of ATP, ADP and AMP being 507, 427 and 347 g mol⁻¹, respectively. A molecular weight cut-off (MWCO) from 720 to 2000 Da was selected which allowed us to assess 7 different membranes for the study: NP010, GR95PP, 7450, 7470 PHT, GE and GK. It has to be noted that, according to the data in Table 4, no correlation was observed between water permeabilities (measured at a pressure of 4 bars), MWCO and materials of the different membranes. The effect of the pressure on permeate flux for the different membranes was evaluated using the model solution (AMP (0.04 g L⁻¹), ADP (0.52 g L⁻¹), ATP (0.15 g L⁻¹) and (CoAS)₂ (0.29 g L⁻¹) with a total concentration of 1.00 g L⁻¹). It was observed for all membranes that the higher the pressure, the faster the flow is in the tested pressure range. As for the permeate flux, it appeared that NP010 and GK were the most efficient membranes in the tested pressure range (Fig. 2). It has to be noted that due to the design of our screening system, the maximum pressure applied to the membrane was not the highest preconized by the manufacturer. However, it did not affect our study as the best results regarding retention of (CoAS)₂ and rejection of ATP, ADP and AMP were observed at the lowest pressures³⁷. Indeed, the experimental data show that the retention of all the compounds is higher as the pressure rise which can be due to the evolution of polarization concentration or the pore sizes. NP010 showed a high retention profile for all compounds which was not suitable for the purification of (CoAS)₂, whereas GK membrane presented high retention capacity for (CoAS)₂, acceptable for ATP and ADP and low for AMP (Fig. 3). These results can be explained by the difference in pore sizes (MWCO of 1000 and 3500 Da for NP010 and GK respectively) and membrane charges—even though no




Figure 3. Effect of pressure (TMP) on the compounds' retention for (A) NP010 and (B) GK membranes with model solution. (●) (CoAS)₂, (●) ATP, (●) ADP, (●) AMP.




Figure 4. Effects of concentrations on permeate flux (J_v) as a function of transmembrane pressure (TMP). (●) 1.51 g L⁻¹, (●) 2.43 g L⁻¹, (●) 5.19 g L⁻¹, (●) 10.71 g L⁻¹.

detail is given for the material of GK (modified polyamide), a difference in the isoelectric points (2.5 and 3.5 for NP010 and GK respectively) show that the two membrane have different charges. Overall, the best compromise between permeate flux and retention profile was obtained for GK membrane at 4 bars, with a retention of 97% for (CoAS)₂, 62% for ATP, 47% for ADP and 8% for AMP and a flux of 43.62 L.h⁻¹.m⁻². The latter was therefore chosen for the rest of the study.

Influence of the solution concentration on performance parameters. The influence of the total compounds solution concentration on the permeate flux and retention profile of the GK membrane was then evaluated in order to intensify the process and reach high productivity rate while decreasing water consumption. A stock solution of (CoAS)₂, ATP, ADP and AMP, obtained by enzymatic synthesis, was therefore used to give access to solutions at 1.51, 2.43, 5.19 and 10.71 g L⁻¹ of total compounds³². These concentrations were chosen to increase dry matter in solution without applying a too large concentration polarization to the system. As expected, a decrease in the permeate flux was observed as the concentration increases. It has to be noted that the 10.71 g/L concentration does not follow this tendency since the experiment was carried out with a new flat sheet. Indeed, it is well known that significant variability in term of permeability is observed between different flat sheets and good repeatability can only be observed when using spiral membrane. However, although this diminution is relatively significant at high pressure (10 bars), it is negligible at our optimum pressure of 4 bars (Fig. 4). Moreover, (CoAS)₂ discrimination vs. ATP and ADP increase as the solution concentration increase. However, it was observed that (CoAS)₂ retention decreased as the solution concentration increased with an important gap between 5.19 and 10.71 g L⁻¹ (Table 1).

These data allowed us to predict (CoAS)₂ purity and losses during a diafiltration using the general formula (Eq. 9) and therefore identify the best compromised concentration. A diafiltration volume of 3 was chosen to compare the different conditions. The predicted losses remained below 10% for the 1.51, 2.43 and 5.19 g L⁻¹ concentrations, and significantly dropped for the 10.71 g L⁻¹ concentration (21%) with no important gain in term of purity (Table 2). By correlating permeate flux (J_v) (Fig. 4) and predicted (CoAS)₂ losses/purity, the best compromised concentration 5.19 g L⁻¹ was chosen to perform the diafiltration.

| Concentration (g L ⁻¹) | (CoAS) ₂ vs. ATP (%) | (CoAS) ₂ vs. ADP (%) | (CoAS) ₂ vs. AMP (%) | (CoAS) ₂ retention (%) |
|------------------------------------|---------------------------------|---------------------------------|---------------------------------|-----------------------------------|
| 1.51 | 21.12 ± 0.09 | 46.18 ± 0.31 | 84.67 ± 1.16 | 97.87 ± 0.15 |
| 2.43 | 22.92 ± 0.22 | 43.89 ± 0.89 | 80.33 ± 0.50 | 98.02 ± 0.20 |
| 5.19 | 29.13 ± 0.08 | 49.73 ± 0.21 | 77.73 ± 0.54 | 97.23 ± 0.09 |
| 10.71 | 33.07 ± 0.41 | 54.53 ± 0.03 | 70.29 ± 0.64 | 92.00 ± 0.43 |

Table 1. Discrimination profile and (CoAS)₂ losses at 4 bars.

| Total compound solution concentration (g L ⁻¹) | Initial (CoAS) ₂ concentration (g L ⁻¹) | Final (CoAS) ₂ purity (%) | Total (CoAS) ₂ losses (%) | Final (CoAS) ₂ concentration (g L ⁻¹) |
|--|--|--------------------------------------|--------------------------------------|--|
| 1.51 | 0.58 | 68 | 6 | 0.55 |
| 2.43 | 0.94 | 67 | 6 | 0.88 |
| 5.19 | 2.02 | 71 | 8 | 1.86 |
| 10.71 | 4.17 | 74 | 21 | 3.29 |

Table 2. Predicted (CoAS)₂ losses at 4 bars and diafiltration volume 3.




Figure 5. Experimental filtration set-up used for diafiltration experiments.

Purification of oxidized coenzyme A via diafiltration process. Total compounds solution concentration of 5.19 g L⁻¹ was therefore used in a diafiltration set-up in order to purify (CoAS)₂ (Fig. 5). A diafiltration volume of 5 was determined to be necessary to reach a purity ≥ 85%. However, the technical constraint of the device forced us to apply a DV of 4.8. The evolution of (CoAS)₂ purity and loss as a function of diafiltration volume (DV), as well as the evolution of permeate flux (J_v) and diafiltration volume (DV) as a function of time, were assessed (Fig. 6). A poor loss of flux (<7%) and no significant fouling were observed during the diafiltration, by comparing water permeabilities before and after diafiltration, which suggests that not only this technology is very well adapted to this type of solutions, but also that the membrane can be recycled and used for several runs. A lower than expected (CoAS)₂ purity of 68% was reached at the end of the diafiltration, and slightly higher than expected losses of 19% (vs. 13% predicted) were observed (Fig. 6A). The difference between the predicted and experimental purity can be explained by the stabilization of the system at the beginning of the diafiltration with small increase in purity observed between the diafiltration volume 0 and 1 (3% increase in




Figure 6. (A) Evolution of (CoAS)₂ purity (●) and loss (●) as a function of diafiltration volume (DV) during dia-ultrafiltration process with 5.19 g L⁻¹ solution. (B) Evolution of permeate flux (Jv) (●) and diafiltration volume (DV) (●) as a function of time, with 5.19 g L⁻¹ solution.

purity instead of 7–8% expected), followed by a linear increase between 1 and 4.8 (Fig. 6A). By extrapolating the results, a purity of 85% could be obtained between 7 and 8 diafiltration volumes with an estimated 30% loss of (CoAS)₂ content. Overall, the best system to purify (CoAS)₂ from ATP, ADP and AMP is using a GK membrane at a TMP of 4 bars with a total compounds concentration solution of 5.19 g L⁻¹. Using these conditions, we were able to isolate 365 mg of (CoAS)₂ at a purity of 68% from a 225 mL crude solution. It has to be noted that these results can be greatly improved, especially in terms of productivity and purity, by using an experimental setup that would allow a larger membrane surface.

Discussion

The use of cross-flow diafiltration for the purification of (CoAS)₂ appeared to be a very good alternative solution to the existing ion exchange chromatography methodology. The membrane screening, evaluation and implementation of the GK membrane allowed us to show the high potential of this process, but it also provided us with data that can allow to confirm if the economy linked to this cofactor can be reversed or not. In the best conditions of our system, the productivity of our diafiltration system is 40.5 mg of 68% pure (CoA)₂ per hour. Although this number seems to be quite small, it is important to note that the scale up possibilities are still to be explored and that this technology is already use in the industry (e.g. for water treatment). Indeed, by simply using a larger membrane surface, we can reach better productivity. The limits of this approach lie in the fact that it is necessary to have an adapted equipment that can handle large membrane surface and that the manufacturer produce large surface. In the case of GK membrane from Suez Water Technologies & Solutions, the larger commercial surface is 33.8 m² in a spiral folding. It has both advantages to have a large active area coupling with a minimal carter size (101 cm high carter with a 20.1 cm diameter). Using such membrane would allow to reach a productivity of 174 g of 85% pure (CoAS)₂ per cm consider that we have comparable flux that the one observed in our study which used plane GK membrane. Even if we consider a bad scenario with a flux divided by a factor 2 because of the folding, the productivity would still be very high with 87 g per hour. This will therefore significantly drop the production cost of (CoAS)₂, will allow its production at an industrial scale and so will unlock the development of CoA-dependent biocatalytic systems.

Furthermore, the environmental impact of both chromatography and membrane methods was assessed through the measurement of the process mass intensity (PMI). In the chromatography and charcoal adsorption/desorption system, after binding (CoAS)₂, ATP, ADP and AMP onto DOWEX anion exchange resin, increasing concentrations of LiCl are used to elute ATP, ADP, AMP and (CoAS)₂, the latter being eluted by 600 mM LiCl. The volume of the solution is then reduced by evaporation of the water and (CoAS)₂ adsorbed on activated charcoal. Excess LiCl is removed by rinsing the activated charcoal with deionized water, then (CoAS)₂ is eluted with a 40% acetone solution containing 0.028% ammonia. The solution is then concentrated under reduced pressure and the residual water removed by freeze-drying to yield the desired product. It has to be noted that this chromatographic method (without considering the charcoal step) is less time consuming—5 h of elution—and that smaller losses were observed (~8%). For this method, a 650 × 25 mm DOWEX 1 × 2 anion exchange column, 53.5 g of LiCl, 20 g of activated charcoal, 4 L of water and 200 mL of acetone containing 0.028% ammonia are necessary to isolate 1 g of (CoAS)₂ at a 82% purity (Fig. 6). Whereas in the membrane-based process described in this study, the same quantity of (CoAS)₂ can be obtain with the same level of purity while avoiding the use of any other—toxic/hazardous—reagent. It is also noteworthy to mention that the diafiltration process can be readily optimized to recycle the water, as shown in Fig. 7 (dashed lines).

In order to quantitatively assess the difference between the two methods in terms of sustainability, the PMI and the simple PMI (sPMI which excludes solvents) for both systems were calculated using the following formulas:

$$PMI = \frac{\sum m(\text{total compounds}) + \sum m(\text{solvents})}{m(\text{desired product})} \quad (1)$$




Figure 7. (A) Purification of $(\text{CoAS})_2$ through chromatography-charcoal adsorption/desorption strategy. (B) Purification of $(\text{CoAS})_2$ through cross-flow dia-filtration strategy.

| | Input compounds | Masse (g) | Output compound | Masse (g) | PMI | sPMI | |
|------------------------|-----------------|-------------------|-----------------|-------------------|-----|--------|-------|
| Classic chromatography | Reagents | ATP | 0.287 | $(\text{CoAS})_2$ | 1 | 372.00 | 58.40 |
| | | ADP | 1.22 | | | | |
| | | AMP | 0.087 | | | | |
| | | $(\text{CoAS})_2$ | 1.095 | | | | |
| | | HCl | 1.93 | | | | |
| | | Hydroxylamine | 0.784 | | | | |
| | Solvents | Acetone | 313.6 | | | | |
| | | Water | 4000 | | | | |
| Diafiltration | Reagents | ATP | 0.38 | $(\text{CoAS})_2$ | 1 | 3.55 | 3.55 |
| | | ADP | 1.61 | | | | |
| | | AMP | 0.115 | | | | |
| | | $(\text{CoAS})_2$ | 1.45 | | | | |
| | Solvent | Water | 4000 | | | | |

Table 3. The calculations of the PMI and sPMI of classic chromatography and diafiltration.

$$sPMI = \frac{\sum m(\text{total compounds})}{m(\text{desired product})} \quad (2)$$

In order to have more readable data, the quantity of water was not included in the calculations since it is in large excess compare to the rest of the compounds and is not differentiating (4 Liters of water is necessary in both system in order to obtain 1 g of the desired product). Thereby, the PMIs were calculated to be 372 for the classic chromatography and 3.55 for the diafiltration, meaning that 100 times more chemical waste by weight is produced using the chromatographic method compared to the diafiltration in order to purify the same amount of $(\text{CoAS})_2$. Even by removing the solvent from the calculation (sPMI), we observe a ratio of 14 which is considerable as we must do necessary efforts towards environmentally friendly processes (Table 3).

Finally, in addition to be sustainable, integrated (purification and desalting at the same time) and to have great scale up potential, this strategy allows to unlock the access to $(\text{CoAS})_2$ at a multigram scale and therefore open the road to the development of CoA dependent biocatalytic systems until then little developed because of its prohibitive price. Such development of alternative purification methods is crucial in order to reveal the full potential of biocatalysis at larger scale.

Methods

Chemicals. Model solution and calibration curves were obtained with AMP (TCI, >98%), ADP (TCI, >98%), ATP (Acros Organics, 98%) and $(\text{CoAS})_2$ (Sigma-Aldrich, 85%). The model solution for the membranes screening was composed of AMP (0.04 g L^{-1}), ADP (0.52 g L^{-1}), ATP (0.15 g L^{-1}) and $(\text{CoAS})_2$ (0.29 g L^{-1}) with a global concentration of 1.00 g L^{-1} . The stock solution from the $(\text{CoAS})_2$ enzymatic synthesis was composed of 80 mM of KCl, 40 mM of MgCl_2 , 200 mM of Tris and 19.0 g L^{-1} of $(\text{CoAS})_2$, 5.0 g L^{-1} of ATP, 21.0 g L^{-1} of ADP and 1.5 g L^{-1} of AMP.

| Membrane | MWCO (Da) | Water permeabilities (L h ⁻¹ m ⁻²) | Type | T _{max} (°C) | pH | P _{max} (bar) | Material |
|--------------------------------|---------------|---|------|-----------------------|--------|------------------------|--------------------|
| GE | 1000 for PEG* | 3.06 | UF | 70 | 1–11 | 40 | Modified polyamide |
| GK | 3500 for PEG* | 8.16 | UF | 70 | 1–11 | 27 | Modified polyamide |
| NP010 | 1000 | 12.96 | NF | 95 | 0–14 | 40 | PES** |
| GR95PP | 2000 | 11.05 | UF | 75 | 1–13 | 10 | PES** |
| HYDRACoRe50-PS 7450 | 1000 | 3.82 | UF | 60 | 2–11 | 41 | Sulfonated PES** |
| HYDRACoRe70pHT Series 7470 PHT | 720 | 2.79 | NF | 70 | 1–13,5 | 41 | Sulfonated PES** |

Table 4. Overview of the selected membranes and their specifications. *PEG: Poly(ethylene glycol), **PES: Polyethersulfone.

L⁻¹ of AMP³². The latter was diluted in order to (i) obtain different concentration solutions and (ii) assume a negligible concentration polarization.

HPLC/MS method. The HPLC analyzes were performed on a Dionex Ultimate 3000 (Dionex Corporation, USA) equipped with a diode array detector (260 nm) and an Acclaim Polar Advantage II C18 column 150 mm × 4.6 mm × 3 μm (Thermo scientific). The temperature and the injection volume were 25 °C and 15 μL, respectively. Monosodium phosphate (NaH₂PO₄, 50 mM, solvent A) and acetonitrile (solvent B) were used as mobile phase with a constant flow rate of 1 mL·min⁻¹. Gradient was: 1.2% (B) held 2.5 min, 1.2–7.2% (B) in 5 min, 7.2–11.2% (B) in 2.5 min, 11.2–20% (B) in 3 min, 20–30% (B) in 0.5 min, 30% (B) held 2.5 min, 30% back to 1.2% (B) in 0.5 min, 1.2% (B) held 3.5 min. Samples were filtered on 0.2 μm regenerated cellulose prior injection. Retentions times were as follows: ATP 2.6 min, ADP 3.1 min, AMP 6.1 min, (CoAS)₂ 11.6 min.

Membranes. Seven commercial flat sheet membranes were selected and tested to purify (CoAS)₂: GE and GK from Suez Water Technologies & Solutions (USA), NP010 from Microdyn-Nadir (Germany), GR95PP from Alfa Laval (Sweden) and HYDRACoRe50-PS 7450 and HYDRACoRe70pHT Series 7470 PHT from Hydranautics-Nitto (USA). Most of them were designed for ultrafiltration processes, and the other for nanofiltration, depending on their molecular weight cut-off (MWCO). Tables 4 summarize the properties of the applied membranes and their field of application (given by manufacturers).

Experimental filtration set up. Filtration experiments were carried out in a METCell filtration device, from Evonik Industries (UK), in cross-flow operating mode. METCell is a stainless-steel system, designed to test flat sheet membranes from microfiltration to reverse osmosis, which is regulated with a gas control unit (inert N₂ gas, from 1 to 65 bar). In cross-flow configuration, three filtration cells supported by porous discs (effective area of 39 cm², 13 cm² each), a feed tank (total volume of 600 mL) and a recirculation pump (AEG, 1.2 L/min), compose the system. Three flat sheet membranes can be used at the same time to allow (i) a screening (in total recirculation) to test different membranes (NB: the permeate flow being negligible compared to the retentate flow, the membranes can be considered as being parallel), (ii) a diafiltration or a concentration to increase membrane area. A high-performance liquid chromatography (HPLC) pump (Model 306, Gilson) was added to the system to enable total recirculation and diafiltration mode. A cooling system (Minichiller) and a balance (0.1 g, Sartorius) were also used to regulate the temperature and measure the permeate rate, respectively.

Filtration parameters. Membrane filtration was defined by some parameters based on Darcy's law (Eq. 3), with J_v (L h⁻¹ m⁻²) the permeate flux, L_p (L h⁻¹ m⁻² bar⁻¹) the solvent permeability and TMP (bar) the transmembrane pressure.

$$J_v = L_p \times TMP \quad (3)$$

For solvent (here pure water), the permeate flux was proportional to TMP, based on Darcy's law, with J_0 (m s⁻¹) the solvent permeate flux, TMP (Pa) the transmembrane pressure, μ (Pa.s) the solvent dynamic viscosity and R_m (m⁻¹) the intrinsic membrane resistance.

$$J_0 = \frac{TMP}{\mu \times R_m} \quad (4)$$

As the solvent dynamic viscosity (μ) depends on temperature, during filtration, after evaluating the solvent temperature, the permeate flux was corrected with solvent dynamic viscosity at 20 °C. Then, solvent permeability (L_p) was calculated to evaluate membrane performance and fouling.

During filtration, J_v was calculated by monitoring the permeate volume V_p (L) and applying Eq. (5), where A (m²) is the membrane filtration effective area and Δt (h) the filtration time.

$$J_v = \frac{V_p}{A \times \Delta t} \quad (5)$$

Membrane performance was evaluated by J_v and the rejection R_i (%). Rejection of the compound i was calculated using $C_{p,i}$ and $C_{r,i}$, the concentrations (g L^{-1}) of i in the permeate and the retentate, respectively.

$$R_i = \left(1 - \frac{C_{p,i}}{C_{r,i}}\right) \times 100 \quad (6)$$

During diafiltration, losses and purities were calculated using Eqs. (7) and (8), respectively, at each diafiltration volume (DV, one diafiltration volume corresponding to the initial feed volume). $C_{f,i,0}$ is the concentration in the feed of solute i , at $t=0$ min. $C_{r,i,t}$, $C_{r,j,t}$ and $C_{r,k,t}$ are the concentrations in the retentate of solutes i , j , k during the diafiltration experiments.

$$\text{Loss}_i = \frac{(C_{f,i,0} - C_{r,i,t})}{C_{f,i,0}} \times 100 \quad (7)$$

$$\text{Purity}_i = \frac{C_{r,i,t}}{(C_{r,i,t} + C_{r,j,t} + C_{r,k,t})} \times 100 \quad (8)$$

During diafiltration, losses and purities can be predict using the following general formula.

$$\frac{C_t}{C_0} = \exp \left\{ -\frac{(1 - R_i)V_t}{V_0} \right\} \quad (9)$$

where C_0 , C_t , R , V_0 and V_t are the concentration of the studied chemical at the initial time, the concentration of the studied chemical at any time, the retention rate for the compound i , the volume of the solution at the initial time and the volume of the solution at any time, respectively.

Membrane screening. Selected membranes were placed in the METcell device and washed according to the manufacturer procedure. Afterward, membranes were compacted with reverse osmosis water, in total recirculation mode, at different pressure levels for 15 min until the chosen maximal pressure for each membrane was attained. The compaction step was validated once permeate flux reached stability at maximal pressure. Flux was then monitored using ultra-pure water, in total recirculation mode, for each membrane, at different transmembrane pressures and at room temperature (25 °C). According to Eq. (3), membrane permeabilities were then determined for each membrane. The feed tank was then filled with 700 mL of the model solution. Permeate flux was evaluated at the studied pressure levels using Eq. (5), in total recirculation mode. Once permeate flux reached steady state, for each transmembrane pressure, retentate and permeate samples were collected for HPLC analyzes. Membrane rejection was calculated for each solute, each transmembrane pressure and each membrane, according to Eq. (6). These experiments allowed to determine the best membrane and pressure to use to purify the (CoAS)₂.

Optimization of starting solution concentration, with selected membrane. To limit water consumption used for dilution, four different concentrations of solution (obtained from the stock solution) were tested: 1.51 g L^{-1} , 2.43 g L^{-1} , 5.19 g L^{-1} and 10.71 g L^{-1} of total compounds (all the solutions are with the ATP/ADP/AMP/(CoAS)₂ ratio at 3.3/14/1/12.6). Membrane performances of selected membranes were quantified (in total recirculation mode) in duplicate, after membrane washing/compaction and membrane water permeability evaluation, by determining permeate flux (Eq. 5) and solutes rejections (Eq. 6).

Diafiltration experiments. In order to eliminate ATP, ADP and AMP via membrane filtration, a diafiltration was operated. The selected membrane was placed in the METcell system ($3 \times 13 \text{ cm}^2$), then washed and compacted with reverse osmosis water, in total recirculation mode, until attaining stable permeate flux. Water permeability, with ultrapure water, was then evaluated by measuring permeate flux at different pressures. After filling the feed tank with 200–250 mL of solution at the optimized concentration (obtained from stock solution), the system was set up at selected pressure at 25 °C, in total recirculation. The diafiltration, in continuous mode, started when ultrapure water was added to the feed via HPLC pump, and the permeate collected in vessel. At each diafiltration volume (DV), samples of retentate were collected for HPLC analyzes. Diafiltration was carried out until desired DV (based on Eq. 9) and in duplicate. Afterwards, pressure was released to reach atmospheric pressure and the retentate solution was recovered. Membrane fouling was evaluated by measuring water permeability after the process.

Data availability

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Received: 3 June 2022; Accepted: 22 July 2022

Published online: 29 July 2022

References

1. Pereira, F. B., Guimaraes, P. M. R., Teixeira, J. A. & Domingues, L. Optimization of low-cost medium for very high gravity ethanol fermentations by *Saccharomyces cerevisiae* using statistical experimental designs. *Bioresour. Technol.* **101**, 7856–7863 (2010).

2. Shen, C. R. & Liao, J. C. Metabolic engineering of *Escherichia coli* for 1-butanol and 1-propanol production via the keto-acid pathways. *Metab. Eng.* **10**, 312–320 (2008).
3. Baez, A., Cho, K.-M. & Liao, J. C. High-flux isobutanol production using engineered *Escherichia coli*: A bioreactor study with in situ product removal. *Appl. Microbiol. Biotechnol.* **90**, 1681–1690 (2011).
4. Papanikolaou, S. & Aggelis, G. Lipid production by *Yarrowia lipolytica* growing on industrial glycerol in a single-stage continuous culture. *Bioresour. Technol.* **82**, 43–49 (2002).
5. Gidijala, L. *et al.* An engineered yeast efficiently secreting penicillin. *PLoS ONE* <https://doi.org/10.1371/journal.pone.0008317> (2009).
6. Schmid, G. & Hofheinz, W. Total synthesis of qinghaosu. *J. Am. Chem. Soc.* **105**, 624–625 (1983).
7. Szczebara, F. M. *et al.* Total biosynthesis of hydrocortisone from a simple carbon source in yeast. *Nat. Biotechnol.* **21**, 143–149 (2003).
8. Hansen, E. H. *et al.* De novo biosynthesis of vanillin in fission yeast (*Schizosaccharomyces pombe*) and Baker's yeast (*Saccharomyces cerevisiae*). *Appl. Environ. Microbiol.* **75**, 2765–2774 (2009).
9. Zhang, X., Wang, X., Shanmugam, K. T. & Ingram, L. O. L-Malate production by metabolically engineered *Escherichia coli*. *Appl. Environ. Microbiol.* **77**, 427–434 (2011).
10. Foerster, A., Aurich, A., Mauersberger, S. & Barth, G. Citric acid production from sucrose using a recombinant strain of the yeast *Yarrowia lipolytica*. *Appl. Microbiol. Biotechnol.* **75**, 1409–1417 (2007).
11. Chapman, J., Ismail, A. E. & Dinu, C. Z. Industrial applications of enzymes: Recent advances, techniques, and outlooks. *Catalysts* **8**, 238 (2018).
12. Choi, J. M., Han, S. S. & Kim, H. S. Industrial applications of enzyme biocatalysis: Current status and future aspects. *Biotechnol. Adv.* **33**, 1443–1454 (2015).
13. Prasad, S. & Roy, I. Converting enzymes into tools of industrial importance. *Recent Pat. Biotechnol.* **12**, 33–56 (2018).
14. Goncalves, A. *et al.* The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation. *Biomed. Pharmacother.* **102**, 833–838 (2018).
15. Savile, C. K. *et al.* Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. *Science* **329**, 305–309 (2010).
16. Krell, H. V., Leuchter, A. F., Cook, I. A. & Abrams, M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. *Psychosomatics* **46**, 379–384 (2005).
17. Panesar, P. S., Kumari, S. & Panesar, R. Biotechnological approaches for the production of prebiotics and their potential applications. *Crit. Rev. Biotechnol.* **33**, 345–364 (2013).
18. Kapoor, S., Rafiq, A. & Sharma, S. Protein engineering and its applications in food industry. *Crit. Rev. Food Sci. Nutr.* **57**, 2321–2329 (2017).
19. Akoh, C. C., Chang, S. W., Lee, G. C. & Shaw, J. F. Biocatalysis for the production of industrial products and functional foods from rice and other agricultural produce. *J. Agric. Food Chem.* **56**, 10445–10451 (2008).
20. Liu, M. C. *et al.* A simple and convenient method for the preparation of antioxidant peptides from walnut (*Juglans regia* L.) protein hydrolysates. *Chem. Cent. J.* **10**, 39 (2016).
21. Sa, A. G., de Meneses, A. C., de Araújo, P. H. & de Oliveira, D. A review on enzymatic synthesis of aromatic esters used as flavor ingredients for food, cosmetics and pharmaceuticals industries. *Trends Food Sci. Technol.* **69**, 95–105 (2017).
22. Kumar, D., Savitri, T. N., Verma, R. & Bhalla, T. C. Microbial proteases and application as laundry detergent additive. *Res. J. Microbiol.* **3**, 661–672 (2008).
23. Alfa, M. J. & Jackson, M. A new hydrogen peroxide-based medical-device detergent with germicidal properties: Comparison with enzymatic cleaners. *Am. J. Infect. Control* **29**, 168–177 (2001).
24. Leonardi, R., Zhang, Y.-M., Rock, C. O. & Jackowski, S. Coenzyme A: Back in action. *Prog. Lipid Res.* **44**, 125–153 (2005).
25. Beinert, H. *et al.* A method for the purification of coenzyme A from yeast. *J. Biol. Chem.* **200**, 385–400 (1953).
26. Reece, M. C., Donald, M. B. & Crook, E. M. The evaluation of a process for the preparation of coenzyme A from yeast. *J. Biochem. Microbiol. Technol. Eng.* **1**, 217–228 (1959).
27. Shimizu, S., Tani, Y. & Ogata, K. Synthesis of coenzyme A and its biosynthetic intermediates by microbial processes. *Meth. Enzymol.* **62**, 236–245 (1979).
28. Shimizu, M., Komaki, R., Tani, Y. & Yamada, H. A high yield method for the preparative synthesis of coenzyme A by combination of chemical and enzymic reactions. *FEBS Lett.* **151**, 303–306 (1983).
29. Shimizu, M., Esumi, A., Komaki, R. & Yamada, H. Production of coenzyme A by a mutant of *Brevibacterium ammoniagenes* resistant to oxypantetheine. *Appl. Environ. Microbiol.* **48**, 1118–1122 (1984).
30. Mandel, A. L., La Clair, J. J. & Burkart, M. D. Modular synthesis of pantetheine and phosphopantetheine. *Org. Lett.* **6**, 4801–4803 (2004).
31. Nazi, I., Koteva, K. P. & Wright, G. D. One-pot chemoenzymatic preparation of coenzyme A analogues. *Anal. Biochem.* **324**, 100–105 (2004).
32. Mouterde, L. M. M. & Stewart, J. D. An efficient chemoenzymatic synthesis of coenzyme A and its disulfide. *Org. Process Res. Dev.* **20**, 954–959 (2016).
33. Mouterde, L. M. M. & Stewart, J. D. Isolation and synthesis of one of the most central cofactors in metabolism: Coenzyme A. *Org. Process Res. Dev.* **23**, 19–30 (2019).
34. Stadtman, E. R. & Kornberg, A. The purification of coenzyme A by ion exchange chromatography. *J. Biol. Chem.* **203**, 47–54 (1953).
35. Ogata, K., Shimizu, M. & Tani, Y. A new preparation method of coenzyme A. *Agric. Biol. Chem.* **34**, 1757–1759 (1970).
36. Shimizu, M., Miyata, K., Tani, Y. & Ogata, K. A new process for the production of coenzyme A and its intermediates with a microorganism. *Biochim. Biophys. Acta* **279**, 583–586 (1972).
37. The integrality of the results is presented in table S-4.

Acknowledgements

This work was supported by the Région Grand Est, Conseil Départemental de la Marne and Grand Reims.

Author contributions

L.M.M.M.: conceived the research. L.M.M.M.: supervised the research. G.W. and M.C.: performed the membrane screening in the METcell system. GW: performed the diafiltrations in the METcell system. F.B. and M.M.J.L.: performed the HPLC analyses. L.M.M.M. and G.W.: analyzed the HPLC data. L.M.M.M.: provided the technical guidelines. L.M.M.M. and F.A.: reviewed the results. L.M.M.M. and G.W.: wrote and drafted the article. L.M.M.M. and F.A.: reviewed and approved the article.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-17250-8>.

Correspondence and requests for materials should be addressed to L.M.M.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022